High Prevalence of Long COVID in Common Variable Immunodeficiency: An Italian Multicentric Study, 2024, Villa et al.

Discussion in 'Long Covid research' started by SNT Gatchaman, Feb 7, 2024.

  1. SNT Gatchaman

    SNT Gatchaman Senior Member (Voting Rights)

    Messages:
    5,003
    Location:
    Aotearoa New Zealand
    High Prevalence of Long COVID in Common Variable Immunodeficiency: An Italian Multicentric Study
    Villa, Annalisa; Milito, Cinzia; Deiana, Carla Maria; Gambier, Renato Finco; Punziano, Alessandra; Buso, Helena; Bez, Patrick; Lagnese, Gianluca; Garzi, Giulia; Costanzo, Giulia; Giannuzzi, Gloria; Pagnozzi, Chiara; Dalm, Virgil A. S. H.; Spadaro, Giuseppe; Rattazzi, Marcello; Cinetto, Francesco; Firinu, Davide

    The long-term effects of SARS-CoV-2 infection represent a relevant global health problem. Long COVID (LC) is defined as a complex of signs and symptoms developed during or after SARS-CoV-2 infection and lasting > 12 weeks. In common variable immunodeficiency (CVID) patients, we previously reported higher risk of hospitalization and death during SARS-CoV-2 infection, as well as prolonged swab positivity and frequent reinfections.

    The aim of the present study was to assess the risk of LC in an Italian cohort of CVID patients. We used a translated version of the survey proposed by Centers for Disease Control and Prevention (CDC) to collect data on LC.

    In the enrolled cohort of 175 CVID patients, we found a high prevalence of LC (65.7%). The most frequent LC symptoms were fatigue (75.7%), arthralgia/myalgia (48.7%), and dyspnea (41.7%). The majority of patients (60%) experienced prolonged symptoms, for at least 6 months after infection. In a multivariate analysis, the presence of complicated phenotype (OR 2.44, 95% CI 1.88–5.03; p = 0.015), obesity (OR 11.17, 95% CI 1.37–90.95; p = 0.024), and female sex (OR 2.06, 95% CI 1.09–3.89; p = 0.024) significantly correlated with the development of LC.

    In conclusion, in this multicenter observational cohort study, we demonstrated that CVID patients present an increased prevalence of LC when compared to the general population. Improved awareness on the risk of LC in CVID patients could optimize management of this new and alarming complication of SARS-CoV-2 infection.

    Link | PDF (Journal of Clinical Immunology)
     
    Ash, Jacob Richter, Kalliope and 4 others like this.
  2. rvallee

    rvallee Senior Member (Voting Rights)

    Messages:
    13,001
    Location:
    Canada
    Even discounting the many decades of precedent, we are closing in on 4 years. Come on, this excuse is close to getting old enough to start kindergarten.
     
  3. NelliePledge

    NelliePledge Moderator Staff Member

    Messages:
    13,922
    Location:
    UK West Midlands
  4. Ash

    Ash Senior Member (Voting Rights)

    Messages:
    1,236
    Location:
    UK
    Is this something we should all be tested for as pwME if it’s true to its name and relatively common?
     
  5. Jonathan Edwards

    Jonathan Edwards Senior Member (Voting Rights)

    Messages:
    14,082
    Location:
    London, UK
    Depends on whether you think 1 in 30,000 is common. I am not so sure.
     
    FMMM1, EndME and Ash like this.
  6. Ash

    Ash Senior Member (Voting Rights)

    Messages:
    1,236
    Location:
    UK
    I thought you might say something like this! And I am delighted that you did. Is it so far down the list as to be a real long shot then?
     

Share This Page